EBV, HSV, and the Promise of EBOO Therapy: A Virology Perspective on Viral Persistence and Advanced Detoxification

As a clinician with deep understanding in virology and functional medicine, I see patients every week struggling with the long-term effects of Epstein-Barr Virus (EBV) and Herpes Simplex Virus (HSV). These ubiquitous herpesviruses infect the vast majority of adults worldwide—EBV in over 90% and HSV-1/HSV-2 in 50–80%—yet conventional medicine offers no hope or cure. Patients often present with chronic fatigue, recurrent outbreaks, autoimmune flares, brain fog, or unexplained inflammation long after the initial infection.

At PCP Health, we are committed to evidence-informed, integrative approaches that address the root drivers of chronic illness. One therapy generating significant clinical interest is EBOO (Extracorporeal Blood Oxygenation and Ozonation)—sometimes referred to as EBOO 2 in advanced protocols. This cutting-edge treatment circulates blood outside the body, oxygenates and ozonates it under controlled conditions, filters out inflammatory mediators and toxins, and returns the revitalized blood to the patient. Emerging research and clinical observations suggest EBOO may help manage persistent viral activity, modulate immunity, and support systemic detoxification—including potential benefits against environmental toxins like microplastics.

Understanding EBV and HSV: Masters of Latency

EBV (human herpesvirus 4) and HSV-1/HSV-2 establish lifelong latency in B cells (EBV) or sensory neurons (HSV). After primary infection, the viruses integrate into host DNA or maintain episomal genomes, evading immune detection through sophisticated mechanisms:

Immune evasion: Downregulation of MHC class I molecules and expression of latency-associated transcripts.

Periodic reactivation: Triggered by stress, immunosuppression, or co-infections, leading to low-level viremia or symptomatic flares.

Associated conditions: EBV is linked to chronic fatigue syndrome (CFS/ME), multiple sclerosis, lymphoma, and autoimmune diseases. HSV contributes to recurrent oral/genital lesions, Bell’s palsy, and, in rare cases, encephalitis.

Standard antivirals (e.g., acyclovir, valacyclovir) suppress replication during active phases but do not eradicate latent reservoirs. This is where adjunctive therapies like EBOO may offer unique value.

What Is EBOO Therapy?

EBOO represents the most advanced form of ozone therapy. Blood (up to 4–6 liters per session) is drawn via a closed-loop extracorporeal circuit, exposed to a precise medical-grade oxygen-ozone mixture (typically 0.5–1 μg/mL), oxygenated, filtered, and returned to the patient over 45–60 minutes. At PCP-Health, we utilize an extra step, by passing the return blood thru a machine that utilizes all spectrums of light and frequency that is designed specifically to kill a virus, or bacteria. Unlike standard autohemotherapy (which treats small blood volumes), EBOO allows large-volume processing, making the treatment more efficient.

Pioneering work by Di Paolo and colleagues demonstrated that EBOO safely treats large blood volumes while generating beneficial oxidative byproducts (e.g., lipid peroxides) that trigger antioxidant defenses and immune modulation without significant oxidative damage to erythrocytes.

Mechanisms of Action: Why EBOO May Help with Persistent Viruses

Ozone (O₃) is a powerful oxidant. In controlled medical application, it exerts pleiotropic effects:

1. Direct antiviral activity — Ozone oxidizes viral envelope lipids and proteins, inactivating free virions. While latent intracellular virus is protected, reactivating virus in circulation becomes vulnerable.

2. Immune modulation — Increases cytokine balance (e.g., ↑ IL-2, balanced Th1/Th2 response), activates natural killer cells, and enhances phagocytosis.

3. Improved oxygenation and microcirculation — Counteracts hypoxia common in chronic viral states.

4. Anti-inflammatory effects— Reduces NF-κB-driven inflammation.

Peer-reviewed evidence supports these mechanisms in viral contexts. A 2022 review detailed ozone’s biochemical actions against emerging viruses, including envelope disruption and redox signaling.

Clinical Evidence for EBV and HSV

While large randomized trials are still needed, promising case reports and observational data exist:

In two patients with EBV- and HSV-associated viral urticaria-angioedema, ozone therapy (including systemic approaches) led to rapid resolution of symptoms and normalization of antibody titers, attributed to ozone’s antiviral and immunomodulatory “autovaccine” effect.

A 2022 observational case series using ozonized saline solution in post-EBV fatigue syndrome showed statistically significant improvement in Fatigue Severity Scale scores and select laboratory markers (e.g., IL-2, EBV antibody trends) with no adverse effects.

Broader ozone therapy literature, including EBOO studies in peripheral arterial disease and chronic infections, consistently reports improved clinical outcomes, reduced inflammatory markers, and better quality of life in patients with viral burdens.

At PCP Health, we have observed similar trends in patients with chronic EBV/HSV reactivation: reduced fatigue, fewer outbreaks, and improved cognitive function when EBOO is integrated into a comprehensive protocol.

Beyond Viruses: Detoxification and Microplastics

Modern life exposes us to microplastics—tiny plastic particles now found in blood, tissues, and even the placenta. While no therapy can claim to “cure” all toxin burdens, EBOO’s filtration step combined with ozone’s oxidative power shows promise in supporting detoxification.

Ozone-based advanced oxidation processes are highly effective at degrading microplastics in environmental water treatment (achieving 45–92% removal in controlled studies). In humans, a 2025 case report documented marked reduction in urinary excretion of environmental toxins following EBOO, suggesting enhanced clearance of accumulated xenobiotics. Ongoing research is exploring whether EBOO’s filtration and redox modulation can similarly mobilize and eliminate microplastics and other persistent organic pollutants.

Is EBOO Right for You?

EBOO is not a standalone “cure” for EBV or HSV—latency remains a biological reality—but it represents a powerful adjunctive tool for patients with chronic symptoms refractory to conventional care. It is particularly well-suited for those with:

- Documented EBV/HSV reactivation and chronic fatigue

- Autoimmune overlap syndromes

- Environmental toxin burden or Long COVID-like presentations

- Poor response to oral antivirals or supplements alone

Another symptom that EBOO has been showing promising developments is NEUROPATHY. Specially, in the initial stages

Sessions are well-tolerated, performed in-office, and typically involve a detailed treatment plan, over several weeks, or months.

Important Medical Disclaimer: EBOO is considered an integrative therapy. While supported by mechanistic studies and clinical observations, it is not FDA-approved specifically for viral eradication or microplastic removal. Results vary by individual. Always consult a qualified provider for personalized evaluation, including baseline viral serologies, toxin panels, and safety screening.

If you’re battling persistent EBV, HSV, fatigue, or suspect environmental toxicity, schedule a consultation at PCP Health. Our team integrates advanced virology insights with cutting-edge therapies like EBOO to help you reclaim your health.

References:

Di Paolo N, et al. (2005). Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy. *Redox Report*, 10(3):121-130.

Manfredi G, Apuzzo D. (2020). Successful Ozone Treatment of EBV and HSV-Related Viral Urticaria. *Frontiers in Medical Case Reports*, 1(2):1-6.

De Coninck D. (2022). Ozonised Saline Solution in treating Post-EBV-Fatigue Syndrome. Case Report and review of the literature. *Ozone Therapy Global Journal*, 12(1):19-39.

Cenci A, et al. (2022). Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases. *International Journal of Molecular Sciences* (review on redox and antiviral effects).

EBOO Therapy & EBV, HSV

Additional supporting reviews: Bocci V. (multiple publications on ozone biology); environmental ozonation studies on microplastics (e.g., Dung et al., 2026 review in PMC).